
Ryght AI offers a secure, AI-powered platform designed to revolutionize clinical trials by streamlining operations and accelerating timelines. Their core offering is an 'AI digital twin' of global clinical trial sites, enabling precise matching of trial protocols to optimal sites and predicting their success. This facilitates faster site identification, feasibility assessment, selection, and activation. The platform serves Sponsors by helping them identify and activate the best sites with minimal competition, CROs by providing AI tools for site and patient projections, and Research Sites by offering access to sponsored trials without EMR integrations or PHI requirements. Ryght AI leverages Generative and Agentic AI technologies to connect a global network of research sites, providing enhanced access, activation, and efficiency for biotech, pharma, and CRO partners worldwide.

Ryght AI offers a secure, AI-powered platform designed to revolutionize clinical trials by streamlining operations and accelerating timelines. Their core offering is an 'AI digital twin' of global clinical trial sites, enabling precise matching of trial protocols to optimal sites and predicting their success. This facilitates faster site identification, feasibility assessment, selection, and activation. The platform serves Sponsors by helping them identify and activate the best sites with minimal competition, CROs by providing AI tools for site and patient projections, and Research Sites by offering access to sponsored trials without EMR integrations or PHI requirements. Ryght AI leverages Generative and Agentic AI technologies to connect a global network of research sites, providing enhanced access, activation, and efficiency for biotech, pharma, and CRO partners worldwide.
Founded: 2023
Headquarters: Laguna Beach, California, United States
Core offering: Generative AI platform (AI digital twin) to accelerate clinical trial site selection, feasibility, and activation
Latest funding: Seed $3.0M (2025-06-12)
Founders: Alex Dickinson; John Crupi; Simon Arkell
Employees: 21
Clinical trial site selection, feasibility assessment, and activation for biopharma / life sciences
2023
Healthcare technology (biopharma / life sciences)
3000000.00 USD
7 investors participated; other investors include Virtue, Top Harvest Capital, Page One Ventures, LDV Partners, Iaso Ventures, AIX Ventures.
“2025 Seed round led by Foothill Ventures; participating investors include Virtue, Top Harvest Capital, Page One Ventures, LDV Partners, Iaso Ventures, and AIX Ventures.”